From the Department of Nephrology (L.Z., Y.M.Z., Z.H.X., G.M.Z., W.G.L.), Interventional Ultrasound Center (L.L.P., M.D.L., M.A.Y.), and Department of Endocrinology (X.W.), China-Japan Friendship Hospital, No. 2, East Yinghuayuan Street, Beijing 100029, People's Republic of China.
Radiology. 2017 Feb;282(2):576-584. doi: 10.1148/radiol.2016151875. Epub 2016 Aug 22.
Purpose To evaluate the safety and efficacy of microwave ablation (MWA) in patients with end-stage renal disease and secondary hyperparathyroidism. Materials and Methods The study protocol was approved by the human ethics review committee. Between March 1, 2014, and June 30, 2015, 51 patients (25 men, 26 women; mean age ± standard deviation, 53.1 years ± 12.9) were enrolled. All patients had at least one enlarged parathyroid gland and secondary symptomatic hyperparathyroidism, which was treated with ultrasonographically (US) guided MWA. The levels of intact parathyroid hormone, serum calcium, phosphorus, and alkaline phosphatase were compared before and after MWA. Paired-sample t tests and paired-sample Wilcoxon signed-rank tests were used to compare treatment outcomes before and after MWA. Results Complete ablation was achieved in all 96 glands in 51 of 120 patients with severe secondary hyperparathyroidism. The mean follow-up time was 11.1 months ± 3.3. The maximum diameter of the glands ranged from 0.5 cm to 4.8 cm (mean, 1.5 cm ± 0.6). The ablation time for each gland was 216.1 seconds ± 130.1. The mean serum intact parathyroid hormone, calcium, and phosphorus levels after MWA (400 pg/mL [400 ng/L; range, 151.3-629.0 ng/L], 2.33 mmol/L ± 0.23, and 1.54 mmol/L ± 0.43, respectively) were significantly lower than those before MWA (1203 pg/mL [1203 ng/L; range, 854.7-1694.5 ng/L], 2.53 mmol/L ± 0.24, and 1.97 mmol/L ± 0.50, respectively; P < .01), while the alkaline phosphatase levels did not change with MWA (P > .05). Ipsilateral recurrent laryngeal nerve injury was seen in one patient (2%). A hematoma developed during one procedure in one patient (2%) and was treated successfully with injection of thrombin. Conclusion US-guided MWA is safe and effective for destroying parathyroid gland tissue in patients with end-stage renal disease and severe secondary hyperparathyroidism. Further experience with the technique is clearly necessary. RSNA, 2016.
目的 评估微波消融(MWA)治疗终末期肾病合并继发性甲状旁腺功能亢进患者的安全性和疗效。
材料与方法 本研究方案经人体伦理审查委员会批准。2014 年 3 月 1 日至 2015 年 6 月 30 日,共纳入 51 例患者(男 25 例,女 26 例;平均年龄±标准差,53.1 岁±12.9 岁)。所有患者均至少有一个甲状旁腺肿大且存在因继发性甲状旁腺功能亢进导致的症状,这些患者均接受了超声引导下的 MWA 治疗。比较 MWA 前后甲状旁腺激素、血清钙、磷和碱性磷酸酶的水平。采用配对样本 t 检验和配对样本 Wilcoxon 符号秩检验比较 MWA 前后的治疗效果。
结果 120 例重度继发性甲状旁腺功能亢进患者中,51 例(96 个腺体)完全消融。平均随访时间为 11.1 个月±3.3 个月。腺体最大直径为 0.54.8 cm(平均 1.5 cm±0.6 cm)。每个腺体的消融时间为 216.1 秒±130.1 秒。MWA 后甲状旁腺激素、血清钙和磷的平均水平(400 pg/mL[400 ng/L;范围 151.3629.0 ng/L]、2.33 mmol/L±0.23 和 1.54 mmol/L±0.43)显著低于 MWA 前(1203 pg/mL[1203 ng/L;范围 854.7~1694.5 ng/L]、2.53 mmol/L±0.24 和 1.97 mmol/L±0.50),而碱性磷酸酶水平在 MWA 后并未发生改变(P>.05)。1 例(2%)患者出现单侧喉返神经损伤。1 例(2%)患者在 1 次手术中出现血肿,通过凝血酶注射成功治疗。
结论 US 引导下的 MWA 治疗终末期肾病合并重度继发性甲状旁腺功能亢进患者是安全且有效的,该技术的进一步应用经验是必要的。
RSNA,2016 年。